# MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

> **NCT01235897** · PHASE1 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 17 (actual)

## Conditions studied

- Advanced Solid Tumors
- Tumors
- Cancer

## Interventions

- **DRUG:** MK-2206
- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01235897
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-03
- **Final completion:** 2013-11
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2014-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235897, "MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01235897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*